Compare Amgen, Inc. (AMGN) vs Ferrari NV (RACE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Ferrari NV — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while Ferrari NV trades at $376.57 (market cap $66.31B). The key difference: Amgen, Inc. is far larger — about 3× Ferrari NV's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | RACE | |
|---|---|---|
Market Cap | $196.12B | $66.31B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $517.65 |
52-Week Low | $271.18 | $314.63 |
Enterprise Value | $241.41B | $67.52B |
Dividend Yield | 2.77% | 1.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Ferrari (RACE) trades at $376.64, up 0.53% with bullish technical signals and strong fundamentals. The stock shows consistent earnings beats, with Q1 2026 EPS of $2.73 exceeding expectations. Revenue grew to $7.15B in 2025, supported by a 22.19% net margin and 41.96% ROE. Recent news highlights include a new EV model launch and ongoing share buybacks, while technical indicators point to support near $372 and resistance at $377.
The outlook remains positive with a consensus price target of $467.50, implying 24% upside. Key risks include execution challenges with new electric vehicles and economic sensitivity. Analyst sentiment is strongly bullish (72% buy ratings), but investors should monitor competitive pressures and margin sustainability amid hybrid transition efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
